Pancreatic Cancer Research

ResearcherChinese Academy of SciencesActive in the last 2 years

Robert M. Hoffman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0049-0041; OpenAlex author ID A5040819666. Sources: OpenAlex.

Their work

Papers
97 (first author 5, last author 42)
Trials
0
Grants
0
Labs led
1
Collaborators
112
Papers, trials and grants by year

2011: 4 papers · 2012: 10 papers · 2013: 6 papers · 2014: 9 papers · 2015: 11 papers · 2016: 4 papers · 2017: 8 papers · 2018: 13 papers · 2019: 4 papers · 2020: 6 papers · 2021: 3 papers · 2022: 5 papers · 2023: 2 papers · 2024: 5 papers · 2025: 6 papers · 2026: 1 paper

Papers 50 of 97

  1. Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells. Last author DOI 10.21873/anticanres.18338↗
  2. Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18186-9↗
  3. Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells. Last author DOI 10.21873/anticanres.17396↗
  4. Simultaneous Targeting of Multiple Hallmarks of Cancer With Recombinant Methioninase, Rapamycin and Chloroquine Is Specific and Synergistic to MiaPaCa-2 Pancre… Last author DOI 10.21873/anticanres.17825↗
  5. Triple Combination of Recombinant Methioninase and the Anti-parasitic Drugs Ivermectin, and Chloroquine Selectively Eradicates Pancreatic Cancer Cells While Sp… Last author DOI 10.21873/anticanres.17828↗
  6. Mucin4 (MUC4) Antibody Labeled with an NIR Dye Brightly Targets Pancreatic Cancer Liver Metastases and Peritoneal Carcinomatosis. Co-author DOI 10.3390/cancers17122031↗
  7. Brightly Visualizing Pancreatic Cancer Margins in Orthotopic Mouse Models with an Anti-CA19-9 Antibody Conjugated to a Near-Infrared Fluorophore. Co-author DOI 10.3390/cancers17162617↗
  8. Exosome Transfer Between Different Co-implanted Human Pancreatic Cancer Cell Lines Occurs in the Primary Tumor and Multiple Metastatic Sites of Nude Mice But N… Last author DOI 10.21873/anticanres.17149↗
  9. First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulte… Last author DOI 10.21873/anticanres.17215↗
  10. Precise Non-invasive Imaging Mouse Model of Pancreatic Cancer: Very Narrow Band-width Laser Fluorescence Excitation of Green Fluorescent Protein Provides Ultra… Last author DOI 10.21873/cdp.10281↗
  11. Extensive DNA Damage and Loss of Cell Viability Occur Synergistically With the Combination of Recombinant Methioninase and Paclitaxel on Pancreatic Cancer Cell… Last author DOI 10.21873/cgp.20475↗
  12. Targeting Human Pancreatic Cancer with a Fluorophore-Conjugated Mucin 4 (MUC4) Antibody: Initial Characterization in Orthotopic Cell Line Mouse Models. Co-author DOI 10.3390/jcm13206211↗
  13. Proof of Principle of Combining Fluorescence-Guided Surgery with Photoimmunotherapy to Improve the Outcome of Pancreatic Cancer Therapy in an Orthotopic Mouse … Co-author DOI 10.1245/s10434-022-12466-4↗
  14. Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study. Co-author DOI 10.3390/jpm13050857↗
  15. Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis… Co-author DOI 10.1016/j.biopha.2022.113733↗
  16. High Incidence of Lymph-node Metastasis in a Pancreatic-cancer Patient-derived Orthotopic Xenograft (PDOX) NOG-Mouse Model. Last author DOI 10.21873/anticanres.15532↗
  17. Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease. Last author DOI 10.21873/anticanres.15734↗
  18. Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft. Co-author DOI 10.21873/invivo.12676↗
  19. Fluorescent Anti-CEA Nanobody for Rapid Tumor-Targeting and Imaging in Mouse Models of Pancreatic Cancer. Co-author DOI 10.3390/biom12050711↗
  20. Color-Coded Imaging of Cancer and Stromal-Cell Interaction in the Pancreatic-Cancer Tumor Microenvironment (TME). First author DOI 10.1007/978-1-0716-1008-4_7↗
  21. Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model. Last author DOI 10.1097/mpa.0000000000001709↗
  22. Exosome Transfer Between Pancreatic-cancer Cells Is Associated With Metastasis in a Nude-mouse Model. Last author DOI 10.21873/anticanres.15063↗
  23. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.10.031↗
  24. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse… Last author DOI 10.1016/j.canlet.2020.07.034↗
  25. Tumor-specific near-infrared nanobody probe rapidly labels tumors in an orthotopic mouse model of pancreatic cancer. Co-author DOI 10.1016/j.surg.2020.02.020↗
  26. The future of tumour-specific fluorescence-guided surgery for pancreatic cancer. First author DOI 10.1016/s2468-1253(20)30123-0↗
  27. The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. Co-author DOI 10.1038/s41598-020-68703-x↗
  28. Brucea javanica Increases Survival and Enhances Gemcitabine Efficacy in a Patient-derived Orthotopic Xenograft (PDOX) Mouse Model of Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14500↗
  29. Role of the tumor microenvironment in pancreatic cancer. Co-author DOI 10.1002/ags3.12225↗
  30. Color-coded Imaging of the Fate of Cancer-cell-derived Exosomes During Pancreatic Cancer Metastases in a Nude-mouse Model. Last author DOI 10.21873/anticanres.13561↗
  31. Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy. Last author DOI 10.21873/anticanres.13726↗
  32. Double-negative T Cells Inhibit Proliferation and Invasion of Human Pancreatic Cancer Cells in Co-culture. Co-author DOI 10.21873/anticanres.13795↗
  33. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Can… Last author DOI 10.1002/jcb.26224↗
  34. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. Last author DOI 10.1016/j.canlet.2018.06.016↗
  35. RT-PCR of peritoneal washings predicts peritoneal pancreatic cancer recurrence. Co-author DOI 10.1016/j.jss.2017.11.009↗
  36. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Last author DOI 10.1016/j.tice.2018.05.003↗
  37. The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic. First author DOI 10.1080/14737140.2018.1477593↗
  38. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived… Last author DOI 10.1080/15384101.2018.1445907↗
  39. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopi… Last author DOI 10.1080/15384101.2018.1480223↗
  40. Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore. Co-author DOI 10.1245/s10434-018-6344-6↗
  41. Genetic and metabolic comparison of orthotopic and heterotopic patient-derived pancreatic-cancer xenografts to the original patient tumors. Co-author DOI 10.18632/oncotarget.23567↗
  42. Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse … Last author DOI 10.18632/oncotarget.24264↗
  43. Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model. Co-author DOI 10.18632/oncotarget.26484↗
  44. Fluorescence-guided Surgery with Splenic Preservation Prevents Tumor Recurrence in an Orthotopic Nude-mouse Model of Human Pancreatic Cancer. Co-author DOI 10.21873/anticanres.12270↗
  45. Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models. Last author DOI 10.21873/anticanres.12430↗
  46. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility co… Co-author DOI 10.1002/jso.24681↗
  47. Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer or… Last author DOI 10.1080/15384101.2017.1315489↗
  48. A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic canc… Co-author DOI 10.18632/oncotarget.11809↗
  49. Locally-applied 5-fluorouracil-loaded slow-release patch prevents pancreatic cancer growth in an orthotopic mouse model. Co-author DOI 10.18632/oncotarget.17370↗
  50. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). Last author DOI 10.18632/oncotarget.17667↗

Closest collaborators

The 25 strongest of 112 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Bouvet · 73 shared papers, 2011–2026 · strength 6.12
  2. Thinzar Min Lwin · 14 shared papers, 2017–2025 · strength 1.77
  3. Yukihiko Hiroshima · 24 shared papers, 2013–2025 · strength 1.39
  4. Atsushi Suetsugu · 15 shared papers, 2011–2024 · strength 1.28
  5. Kentaro Miyake · 13 shared papers, 2017–2022 · strength 1.02
  6. Sei Morinaga · 5 shared papers, 2024–2025 · strength 1.01
  7. Takashi Murakami · 15 shared papers, 2014–2019 · strength 0.93
  8. Surinder K. Batra · 5 shared papers, 2022–2025 · strength 0.93
  9. Kavita B. Mallya · 5 shared papers, 2022–2025 · strength 0.93
  10. Itaru Endo · 16 shared papers, 2013–2020 · strength 0.92
  11. Hiroto Nishino · 6 shared papers, 2020–2023 · strength 0.88
  12. Shinji Miwa · 10 shared papers, 2013–2025 · strength 0.84
  13. Aaron M. Mohs · 4 shared papers, 2023–2025 · strength 0.78
  14. Kei Kawaguchi · 9 shared papers, 2017–2022 · strength 0.77
  15. Michiaki Unno · 9 shared papers, 2017–2022 · strength 0.77
  16. Ali A. Maawy · 16 shared papers, 2013–2017 · strength 0.70
  17. Masahito Shimizu · 5 shared papers, 2017–2024 · strength 0.68
  18. Michael A. Turner · 4 shared papers, 2022–2023 · strength 0.67
  19. Sunidhi Jaiswal · 3 shared papers, 2024–2025 · strength 0.62
  20. Maneesh Jain · 3 shared papers, 2024–2025 · strength 0.62
  21. Yasushi Ichikawa · 8 shared papers, 2014–2024 · strength 0.57
  22. Norihiko Sugisawa · 5 shared papers, 2019–2022 · strength 0.56
  23. Kristin E. Cox · 3 shared papers, 2023–2025 · strength 0.55
  24. Yohei Asano · 2 shared papers, 2025 · strength 0.46
  25. Hisataka Moriwaki · 8 shared papers, 2011–2019 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.